Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell non-Hodgkin lymphoma, belonging to the group of CD30-positive lymphoproliferative disorders, which affects lymph nodes and extranodal sites. It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL.
Biomarker and diagnostic research for anaplastic large cell lymphoma has been reported in the published literature.
1 FDA-approved treatment is available for anaplastic large cell lymphoma, including CRIZOTINIB (XALKORI, approved 2011). An additional 1 compound holds orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Estimated prevalence: 1-9 in 100,000 (Uncommon).
43 clinical trials registered, 20 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 1 PHASE4, 4 PHASE3, 10 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06561048](https://clinicaltrials.gov/study/NCT06561048) |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 7:14 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
European rare disease database
Genetic and Rare Diseases Info Center
XALKORI |
CRIZOTINIB |
— |
2011 |
Available |
The following drugs have received orphan drug designation from the FDA for anaplastic large cell lymphoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
CD30-Targeted Genetically-modified Autologous T-cell immunotherapy | CD30-Targeted Genetically-modified Autologous T-cell immunotherapy | Wu Han Bio-raid Biotech Co., Ltd. | 2024 | — | Designated |
Gene therapy approaches for anaplastic large cell lymphoma have been reported in the published literature.
43 trials found
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma |
PHASE3 |
Corvus Pharmaceuticals, Inc. |
RECRUITING |
[NCT07055477](https://clinicaltrials.gov/study/NCT07055477) | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
[NCT07013565](https://clinicaltrials.gov/study/NCT07013565) | Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL | PHASE2 | New York Medical College | RECRUITING |
[NCT03017820](https://clinicaltrials.gov/study/NCT03017820) | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | PHASE1 | Mayo Clinic | RECRUITING |
[NCT05978141](https://clinicaltrials.gov/study/NCT05978141) | A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | RECRUITING |
203 publications have been identified in PubMed for anaplastic large cell lymphoma. Kisho has analyzed 149 by research type. Research spans Review / Meta-Analysis (30%), Case Report / Case Series (25%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 45 | 30% |
Patient case studies | 37 | 25% |
Laboratory research | 23 | 15% |
Disease patterns and progression | 15 | 10% |
Clinical study results | 12 | 8% |
Other research | 6 | 4% |
Testing and diagnosis research | 6 | 4% |
New treatment approaches | 5 | 3% |
Patel BC (2026). [PMID: 28723027](https://pubmed.ncbi.nlm.nih.gov/28723027/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
Zhang Q (2026). [PMID: 41792044](https://pubmed.ncbi.nlm.nih.gov/41792044/). *Cancer Med*. [Diagnostic / Biomarker]
Nassar K (2026). [PMID: 41732962](https://pubmed.ncbi.nlm.nih.gov/41732962/). *Rev Prat*. [Case Report / Case Series]
Stuver R (2026). [PMID: 42273944](https://pubmed.ncbi.nlm.nih.gov/42273944/). *Haematologica*. [Review / Meta-Analysis]
Caserta S (2026). [PMID: 41905770](https://pubmed.ncbi.nlm.nih.gov/41905770/). *Br J Haematol*. [Review / Meta-Analysis]
Akaishi K (2026). [PMID: 41867344](https://pubmed.ncbi.nlm.nih.gov/41867344/). *Plast Reconstr Surg Glob Open*. [Clinical Trial Publication]
Bosc R (2026). [PMID: 41620260](https://pubmed.ncbi.nlm.nih.gov/41620260/). *Ann Chir Plast Esthet*. [Review / Meta-Analysis]
Schukow C (2026). [PMID: 36944007](https://pubmed.ncbi.nlm.nih.gov/36944007/). *Unknown Journal*. [Case Report / Case Series]
Santanelli Di Pompeo F (2026). [PMID: 41092238](https://pubmed.ncbi.nlm.nih.gov/41092238/). *Aesthet Surg J*. [Other]
Wei W (2026). [PMID: 41225182](https://pubmed.ncbi.nlm.nih.gov/41225182/). *Leukemia*. [Epidemiology / Natural History]
AI-curated news mentioning anaplastic large cell lymphoma
Updated Sep 1, 2026
A recent case report highlights the use of immune checkpoint inhibitors in treating relapsed/refractory anaplastic large cell lymphoma (ALCL). This review of the literature provides insights into potential therapeutic strategies for this challenging condition.
A recent study highlights the diagnostic challenges posed by poorly differentiated lung adenocarcinomas that express both ALK and CD30, which can mimic ALK-positive anaplastic large-cell lymphoma. This finding underscores the need for careful differential diagnosis in clinical settings.
Recent research highlights breast implant-associated anaplastic large cell lymphoma as a heterogeneous T cell disease characterized by active pro-tumor cross-talk and immune suppression. This study provides insights into the disease's complexity, which may inform future therapeutic strategies.